News
Deep Bio launches AI-diagnostic software on prostate cancer .."grants certifications"
2018.12.13
Biospectator

ios-image

Deep Bio announced today that it had released its artificial intelligence (AI) diagnostic products for the first time in the domestic press. The company’s first AI software product ‘Deep Dx’ detects prostate cancer using H&E stained prostate biopsy WSI images.

The founder & CEO of Deep Bio, Sun Woo Kim proposed that the company has completed the preparations to enter the domestic approval process by granting ISO13485:2016 (Quality Management System on Medical Device) and KGMP (Korean medical device manufacturing and quality control standard). He additionally commented that the company is officially ready to step into the overseas market.

◇ DeepDx “ Cancer detection with 10-seconds..includes an automatic pathology report.”

Deep Bio ‘DeepDx’ AI-diagnostic software uses digitally scanned prostate biopsy image to diagnose prostate cancer. Despite the size of the high-resolution image, DeepDx can detect cancer on a WSI image and generate an automatic pathology-like report within 10 seconds.

Kim mentioned, “The pathology reporting guidelines have recommended to particularly include the percentage of Gleason pattern four as it provides clinically significant information on predicting patients prognosis.” The company’s product ‘DeepDx’ can automatically calculate the proportions of each Gleason pattern and further captures the main cancerous areas on images which are included in the report. Deep Bio’s first products were launched at the DPA (Digital Pathology Association) 2018 held in San Diego, USA and will further launch at USCAP & AACR Annual Meeting 2019.

Deep Bio CEO, Kim said, “Many pathologists are surprised at the accuracy of our products performances, and have shown significant interest.” 2019 is expected to become an important year for Deep Bio and its commercialization to expand globally. Kim added, “We are also considering attracting investment from global venture capital companies, and we will extend our service offerings to multinational pharmaceutical companies.

For more information:
http://www.biospectator.com/view/news_view.php?varAtcId=6777